THE p olym or ph on uclear n eutr op h ils (PMN) po s s e s s s ufficie n t p ote ntial to affect both im m un e r es p o ns e an d in flam m ation , h o w e ver it h as no t been yet de s cribed in th e co urs e of m ultip le s cler o s is (MS).
Introduction
Multiple sclerosis (MS) is a dise as e in w hich multifoc al inflammation and damage of the blood -brain barrier and myelin sheath are salie nt pathologic features. Overw he lming evidenc e demons trates that MS is a pre dominantly T-c ell and monoc yte/mac rophageme diated autoimmune disorde r. 1 ,2 Polymorphonuclear ne utrop hils (PMN) have not be en considere d as a ce ll population participating in it. 3 PMN can how e ver ex pre ss immunore gulatory abilities, that has not be en ye t de sc ribe d in the c ourse of MS. Activated in vitro PMN produc e a numbe r of immune mediators including cytokines like IL-1b , IL-4, IL-6, IL-8, IL-10, IL-12, TNF, TGF-b 1. 4 ,5 There fore the re gulatory functions of these ce lls may be postulate d in the c ourse of MS.
PMN in the pe ripheral blood (PB) of MS patients can be primed mainly by inflammatory cytokine s like IL-1, INF-g , or by TNF-a sec re te d by mononuclear ce lls. Hypothetically PMN priming or activation in PB of MS patients may dep end also on compleme nt (especially C5a) immunologic al c omplex es, or certain me tabolite s of the arachidonic ac id (LTB 4 , PAF).
Priming re sults in the enhanced ex p re ssion on PMN of re cep tors for chemokines and other chemotactic pep tide s, 6 priming also enhance s the ex pre ssion of CD11b/CD18 molecules on PMN c ell surface 7, 8 w hich re sults in the indire ct ac tivation of PMN. 9, 10 In the pre sente d pap er w e have suggeste d that PMN priming can be obse rved in MS patie nts p eriphe ral blood.
Patients and methods
Patients (34 total; 19 w omen and 15 men, aged 22-56 years) w ere se lecte d w ith a clinic ally definitive diagnosis of MS 1 1 and w ith Kurtzke Ex panded Disability Status Scale 12 scores 5 or few er and categorized as having the re lapsing-re mitting MS (RR-MS) course for at least 5 years but curre ntly in re mission (REM) (n =13), as having either sec ondary CP-MS for at least 2 ye ars (n =13) or RR-MS and currently ex pe riencing clinical ex ace rbation (REL) of the disease (n = 12). Ex acerbations w ere defined as the appearance of new symptoms or significant w orsening of the old ones, attributabl e to MS, for at least 24 hours w ithout any fever.
The control group c onsiste d of patients w ith other ne urologic al diseas es (OND) (14 total; nine w omen and five men, aged from 24 to 37 ye ars), including those w ith vasomotor headache (n = 8) and ischialgia (n = 6).
Sample collection
The studies w e re performed on PMN of the p eripheral venous blood, c ollec te d into heparin-containin g tubes (10 U/ml).
TNF labelling with fluorescein isothiocyanate (FITC)
The synthesis and biological analysis of the TNF molecules w ere pe rforme d at the Departme nt of Bioorganic Chemistry, Lódź, Poland (Pate nt No. 168858). TNF staining w as done w ith FITC (Serva), according to Shirakaw a e t a l. 13 
Evaluation of TNF-FITC binding to PMN
One hundre d m l of the w hole blood w as inc ubate d w ith TNF-FITC at the conc entration of 1000 ng/ml for 2 h at 4°C. The erythroc ytes w e re lysed, using 1 ml of FACS Lysing Solution (Bec ton Dickinson) for 15 min at room te mpe rature. Ce lls w e re ce ntrifuge d for 5 min at 400 3 g , the n w ashed w ith 3 ml of PBS and suspe nded in 100 m l of PBS. The fluore sce nce intensity of PMN w as measured using a flow c ytometry FACSc an (Be cton Dickinson) and Lysis II softw are. Each measureme nt w as re peated four times and pre sente d here as a me an fluore sce nce inte nsity (MFI). Spe cificity of the binding of TNF-FITC to PMN w as evaluated in blocking ex pe rime nt by pre inc ubation of the PMN w ith non-staine d TNF in ex c ess for 45 min be fore TNF-FITC binding (Fig. 1) .
Evaluation of the expression of CD11a, CD11b and CD18 molecules of LFA-1 and Mac-1 intregine and CD10 and CD13 Ag of neutral endopeptidase (NEP) and aminopeptidase N (APN) on PMN 
Results
The MFI of the PMN incubated w ith FITC-TNF w as highest in the group w ith ex ace rbation of RR-MS (REL) ( Table 1 ) and the value w as significantly higher (P< 0.01) compared w ith the other groups of MS patients and to OND. In the c ourse of CP-MS and in MS re mission (REM) the te ste d values w ere in the range observed in the control group (OND).
Ex pre ssion of CD10, CD13 Ag and CD11b/CD18 molecules on PMN w as signific antly inc re ased in REL (P< 0.05 and P< 0.01) c ompared w ith that ex amined in CP-MS, REM and OND (Table 1) . CD11a ex pre ssion on PMN in REL w as the same as in CP-MS patients and in OND. In the c ourse of CP-MS only ex pre ssions of CD11b and CD18 but not CD10 and CD13 w ere significantly inc re as ed (P<0.01 and P<0.05) compared w ith OND. Ex pre ssions of CD11a, CD11b and CD10 w ere markedly diminishe d (P< 0.01 and P< 0.05) during re mission of MS compare d w ith the controls (Table 1) .
Discussion
It has be en proved in pre vious studie s that there is a more inte nsive inflammatory re sp onse in ac ute ex ace rbations of RR-MS patie nts than in the c ourse of CP-MS. 2 The obtained data sugge st that re lapsingre mitting MS follow s c ycles of immunologic al activation as a re sult of Th-1 re sponse (ex ac erbation), w hich is then follow e d by a suppre ssor re sponse that dow nre gulates inflammation (re mission).
1 ,2 In CP-MS there is continuous low -grade inflammation w ith no obvious ex acerbations or re missions.
The involvement of TNF in immunopathologic al proce sse s in MS has alre ady be en know n for quite some time .
14 This cytokine is also one of the most pote nt priming factors for PMN in vitro .
7,1 5 We suggest that se rum TNF of patients w ith ac ute ex ace rbations of RR-MS or in low er de gree in the course of CP-MS can be the main p riming fac tor of PMN.
TNF in v itro stimulates the ex pre ssion of many of the PMN surface molecules. Simultaneously TNF stimulates its ow n re ce ptors ex pre ssion (TNF-R) on PMN. 16 This has be e n c onfirmed in our study as the inc re as ed TNF binding to PMN in the c ourse of ac ute ex ace rbations of MS. We have obse rved also the significant inc re as e of the CD10, CD13 Ag and CD11b/CD18 molecule ex pre ssion on PMN of MS patients, mainly in the c ourse of ex ac erbation compared w ith MS re mission and w ith OND groups. This may be a sign of priming of PMN in MS ex acerbation and to a low er degre e in the c ourse of CP-MS.
Podikoglou e t a l. 3 have show n that the typic al functions of PMN, like adhere nce , chemotax is, phagocytosis or bacte ricidal action have be en significantly diminishe d in PB of MS patients. The re sults that w e have obtained in our study correspond w ith Goto e t a l.. 1 7 In some e arlie r obse rvation s Aoki e t a l. 18 and Guarnieri e t a l. 1 9 have show n that the inc re as ed intrac ellular ne utral proteinase and medullasine c onc entrations can be the symptom of PMN activation in the blood of patie nts w ith acute ex ac erbation of MS.
PMN c ontain large amounts of proteinases, like NEP and APN, in their intra cellular granules.
2 0,21 The inc re as ed ex pre ssion on in v itro stimulated PMN is a re sult of rapid transloc ation of an intrac ellular pool to the c ell surface . 22 ,2 3 The incre as ed ex pre ssion of CD11b/CD18-Mac -1 mole cules probably re sults from their rapid shift from internal granule s to the surfac e of primed PMN. Such proce ss has not be en observe d in CD11a/CD18 mole cules of LFA-1 integrine ex pre ssion of in vitro prime d PMN. 24, 25 In our studies w e have not notice d the inc re ased ex pre ssion of CD11a molecule on PMN of MS p atie nts w ith acute ex acerbations or in the c ourse of CP-MS. In our opinion, the se can sugge st PMN p riming in patients w ith active MS. Activated PMN c an produc e ox yge n and nitrogen spe cie s, some matrix de grading metalloprote inases and some c ytokine s. 5 ,26 Priming is a pre liminary e ve nt be fore re c eptor-induce d stimulation of PMN. It is the n a sign of these c ells' hype rre ac tivity. PMN priming features obse rved in the PB of patie nts w ith active MS sugge st that these c ells may participate in the MS immunopathology.
Po ly m o rp ho nu cle a r n e u tro p hils a nd m u ltiple s cle ro s is
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